keyword
MENU ▼
Read by QxMD icon Read
search

NVAF

keyword
https://www.readbyqxmd.com/read/29655807/temporal-trends-of-time-in-therapeutic-range-and-incidence-of-cardiovascular-events-in-patients-with-non-valvular-atrial-fibrillation
#1
Daniele Pastori, Alessio Farcomeni, Mirella Saliola, Francesco Del Sole, Pasquale Pignatelli, Francesco Violi, Gregory Y H Lip
BACKGROUND: Optimal time in therapeutic range (TTR) of vitamin K antagonists (VKAs) is crucial for cardiovascular events (CVEs) prevention in non-valvular atrial fibrillation (NVAF). The relationship between temporal changes of TTR and the incidence of CVEs has been poorly investigated. We investigated 1) temporal trends of TTR in a long-term follow-up of NVAF patients; 2) the incidence of CVEs according to changes of TTR. METHODS: Prospective observational study including 1341 NVAF outpatients (mean age 73...
April 11, 2018: European Journal of Internal Medicine
https://www.readbyqxmd.com/read/29625717/prospective-observational-study-in-elderly-patients-with-non-valvular-atrial-fibrillation-rationale-and-design-of-the-all-nippon-af-in-the-elderly-anafie-registry
#2
Hiroshi Inoue, Takeshi Yamashita, Masaharu Akao, Hirotsugu Atarashi, Takanori Ikeda, Ken Okumura, Yukihiro Koretsune, Wataru Shimizu, Hiroyuki Tsutsui, Kazunori Toyoda, Atsushi Hirayama, Masahiro Yasaka, Takenori Yamaguchi, Masahiro Akishita, Naoyuki Hasebe, Kazuomi Kario, Yuji Mizokami, Ken Nagata, Masato Nakamura, Yasuo Terauchi, Takatsugu Yamamoto, Satoshi Teramukai, Tetsuya Kimura, Jumpei Kaburagi, Atsushi Takita
BACKGROUND: Although anticoagulation effectively prevents stroke in patients with atrial fibrillation (AF), it has been underused in elderly AF patients for many reasons, mainly because of knowledge gaps regarding cardiovascular treatment of these populations with multiple comorbidities and poor prognosis. The objectives of the All Nippon AF In the Elderly (ANAFIE) Registry are to collect real-world information about the clinical status of patients with non-valvular AF (NVAF) aged ≥75 years, current status of anticoagulant therapy, and prognosis with/without anticoagulation to establish a database for this specific patient population that is increasing remarkably worldwide...
April 3, 2018: Journal of Cardiology
https://www.readbyqxmd.com/read/29621248/adherence-to-rivaroxaban-versus-apixaban-among-patients-with-non-valvular-atrial-fibrillation-analysis-of-overall-population-and-subgroups-of-prior-oral-anticoagulant-users
#3
Colleen A McHorney, Concetta Crivera, François Laliberté, Guillaume Germain, Willy Wynant, Patrick Lefebvre
BACKGROUND: Medication non-adherence can result in poor health outcomes. Understanding differences in adherence rates to non-vitamin K oral anticoagulants (NOACs) could guide treatment decisions and improve clinical outcomes among patients with non-valvular atrial fibrillation (NVAF). OBJECTIVE: To compare adherence to rivaroxaban and apixaban among the overall NVAF population and subgroups of prior oral anticoagulant (OAC) users (e.g., multiple comorbidities, non-adherence risk factors)...
2018: PloS One
https://www.readbyqxmd.com/read/29611105/quality-of-direct-oral-anticoagulant-prescribing-in-elderly-patients-with-non-valvular-atrial-fibrillation-results-from-a-large-urban-health-system
#4
Shakira J Grant, Shawn Kothari, Phyllis A Gimotty, Nalaka S Gooneratne, Adam Cuker
Non-valvular atrial fibrillation (NVAF) is common in older adults. Oral anticoagulation is indicated to reduce the risk of stroke and systemic embolism, but it also poses a risk of bleeding, particularly in the elderly. Direct oral anticoagulants (DOACs) provide an alternative to warfarin and their use in the treatment of AF is growing. We conducted a retrospective cohort study to assess the quality of DOAC prescribing in elderly patients with NVAF in a large academic health system and to compare practice with consensus best practice recommendations...
April 2, 2018: Journal of Thrombosis and Thrombolysis
https://www.readbyqxmd.com/read/29607894/high-cardiac-troponin-i-is-associated-with-transesophageal-echocardiographic-risk-of-thromboembolism-and-ischemic-stroke-events-in-non-valvular-atrial-fibrillation-patients
#5
Shuhei Tanaka, Tadakazu Hirai, Kyoko Inao, Nobuyuki Fukuda, Keiko Nakagawa, Hiroshi Inoue, Koichiro Kinugawa
BACKGROUND: Abnormalities in the left atrium (LA) detected on transesophageal echocardiography (TEE) are reliable predictors of thromboembolism in patients with atrial fibrillation (AF). Cardiac troponin I, a marker of subclinical myocardial damage, may also be a predictor of thromboembolic events in patients with AF. The relationship between cardiac troponin I and thromboembolic risk on TEE, however, remains unclear.Methods and Results:TEE and laboratory data, including high sensitivity cardiac troponin I (hs-cTnI) and CHA2 DS2 -VASc score, were analyzed in 199 patients with non-valvular AF (NVAF)...
March 31, 2018: Circulation Journal: Official Journal of the Japanese Circulation Society
https://www.readbyqxmd.com/read/29602837/trends-in-initiation-of-direct-oral-anticoagulant-therapies-for-atrial-fibrillation-in-a-national-population-based-cross-sectional-study-in-the-french-health-insurance-databases
#6
Laetitia Huiart, Cyril Ferdynus, Christel Renoux, Amélie Beaugrand, Sophie Lafarge, Léa Bruneau, Samy Suissa, Olivier Maillard, Xavier Ranouil
OBJECTIVE: Unlike several other national health agencies, French health authorities recommended that the newer direct oral anticoagulant (DOAC) agents only be prescribed as second choice for the treatment of newly diagnosed non-valvular atrial fibrillation (NVAF), with vitamin K antagonists (VKA) remaining the first choice. We investigated the patterns of use of DOACs versus VKA in the treatment of NVAF in France over the first 5 years of DOAC availability. We also identified the changes in patient characteristics of those who initiated DOAC treatment over this time period...
March 30, 2018: BMJ Open
https://www.readbyqxmd.com/read/29602444/tromboc-t-working-group-recommendations-for-management-in-patients-receiving-direct-oral-anticoagulants
#7
Pável Olivera, Miren Gabilondo, Mireia Constans, Dolors Tàssies, Esther Plensa, Verónica Pons, Germán Las Heras, Carmen Jiménez, Desirée Campoy, Anna Bustins, Artur Oliver, Cristina Marzo, Tania Canals, Anna Varela, Marc Sorigue, Eva Sánchez, Gabriela Ene, Granada Perea, Laura Vicente, Meritxell López, María Cerdá, Erik Johansson, M Reyes Aguinaco, Nazly Santos, José Mateo, Joan Carles Reverter, Ángel Moya, Amparo Santamaría
BACKGROUND AND OBJECTIVES: In recent years, direct oral anticoagulants (DOACs) have become an alternative to vitamin K antagonists (VKA) for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) as well as for prevention and treatment of deep venous thrombosis. Pivotal trials have demonstrated non-inferiority and potential superiority compared to warfarin, which increases the options of anticoagulant treatment. In our setting, the Anticoagulant Treatment Units (ATUs) and Primary Care Centres (PCCs) play an important role in the education, follow-up, adherence control and management in special situations of anticoagulated patients...
March 27, 2018: Medicina Clínica
https://www.readbyqxmd.com/read/29597211/associations-between-pre-admission-risk-scores-and-two-year-clinical-outcomes-in-ischemic-stroke-or-transient-ischemic-attack-patients-with-non-valvular-atrial-fibrillation
#8
Keisuke Tokunaga, Hiroshi Yamagami, Masatoshi Koga, Kenichi Todo, Kazumi Kimura, Ryo Itabashi, Tadashi Terasaki, Yoshiaki Shiokawa, Kenji Kamiyama, Shunya Takizawa, Satoshi Okuda, Yasushi Okada, Tomoaki Kameda, Yoshinari Nagakane, Yasuhiro Hasegawa, Satoshi Shibuya, Yasuhiro Ito, Hideki Matsuoka, Kazuhiro Takamatsu, Kazutoshi Nishiyama, Kazuomi Kario, Yoshiki Yagita, Takanari Kitazono, Naoto Kinoshita, Junji Takasugi, Takuya Okata, Sohei Yoshimura, Shoichiro Sato, Shoji Arihiro, Kazunori Toyoda
BACKGROUND: We aimed to clarify associations between pre-admission risk scores (CHADS2, CHA2DS2-VASc, and HAS-BLED) and 2-year clinical outcomes in ischemic stroke or transient ischemic attack (TIA) patients with non-valvular atrial fibrillation (NVAF) using a prospective, multicenter, observational registry. METHODS: From 18 Japanese stroke centers, ischemic stroke or TIA patients with NVAF hospitalized within 7 days after onset were enrolled. Outcome measures were defined as death/disability (modified Rankin Scale score ≥3) at 2 years, 2-year mortality, and ischemic or hemorrhagic events within 2 years...
March 29, 2018: Cerebrovascular Diseases
https://www.readbyqxmd.com/read/29590304/long-term-thromboembolic-risk-in-patients-with-postoperative-atrial-fibrillation-after-coronary-artery-bypass-graft-surgery-and-patients-with-nonvalvular-atrial-fibrillation
#9
Jawad H Butt, Ying Xian, Eric D Peterson, Peter Skov Olsen, Rasmus Rørth, Anna Gundlund, Jonas B Olesen, Gunnar H Gislason, Christian Torp-Pedersen, Lars Køber, Emil L Fosbøl
Importance: New-onset postoperative atrial fibrillation (POAF) is a common complication of coronary artery bypass graft (CABG) surgery. However, the long-term risk of thromboembolism in patients who develop POAF after CABG surgery remains unknown. In addition, information on stroke prophylaxis in this setting is lacking. Objective: To examine stroke prophylaxis and the long-term risk of thromboembolism in patients with new-onset POAF after first-time isolated CABG surgery compared with patients with nonsurgical, nonvalvular atrial fibrillation (NVAF)...
March 28, 2018: JAMA Cardiology
https://www.readbyqxmd.com/read/29590209/patients-with-atrial-fibrillation-and-permanent-pacemaker-temporal-changes-in-patient-characteristics-and-pharmacotherapy
#10
Frederik Dalgaard, Martin H Ruwald, Tommi Bo Lindhardt, Gunnar H Gislason, Christian Torp-Pedersen, Jannik L Pallisgaard
BACKGROUND: The management of patients with non-valvular atrial fibrillation (NVAF) with rate-lowering or anti-arrhythmic drugs has markedly changed over the last decade, but it is unknown how these changes have affected patients with NVAF with a permanent pacemaker (PPM). METHODS: Through Danish nationwide registries, patients with NVAF and a PPM were identified from 2001 to 2012. Changes in concomitant pharmacotherapy and comorbidities were tested using the Cochran-Armitage trend test and linear regression...
2018: PloS One
https://www.readbyqxmd.com/read/29582316/major-adverse-cardiovascular-events-in-non-valvular-atrial-fibrillation-with-chronic-obstructive-pulmonary-disease-the-arapacis-study
#11
Valeria Raparelli, Daniele Pastori, Serena Francesca Pignataro, Anna Rita Vestri, Pasquale Pignatelli, Roberto Cangemi, Marco Proietti, Giovanni Davì, William Robert Hiatt, Gregory Yoke Hong Lip, Gino Roberto Corazza, Francesco Perticone, Francesco Violi, Stefania Basili
Chronic obstructive pulmonary disease (COPD) increases the risk of mortality in non-valvular atrial fibrillation (NVAF) patients. Data on the relationship of COPD to major cardiovascular events (MACE) in AF have not been defined. The aim of the study is to assess the predictive value of COPD on incident MACE in NVAF patients over a 3-year follow-up. In the Atrial Fibrillation Registry for Ankle-Brachial Index Prevalence Assessment-Collaborative Italian Study (ARAPACIS) cohort, we evaluate the impact of COPD on the following clinical endpoints: MACE (including vascular death, fatal/non-fatal MI and stroke/TIA), cardiovascular (CV) death and all-cause mortality...
March 26, 2018: Internal and Emergency Medicine
https://www.readbyqxmd.com/read/29582237/locations-and-mucosal-lesions-responsible-for-major-gastrointestinal-bleeding-in-patients-on-warfarin-or-dabigatran
#12
Jennifer M Kolb, Kathryn Friedman Flack, Prapti Chatterjee-Murphy, Jay Desai, Lars C Wallentin, Michael Ezekowitz, Stuart Connolly, Paul Reilly, Martina Brueckmann, John Ilgenfritz, James Aisenberg
BACKGROUND AND AIM: Different oral anticoagulants may be associated with gastrointestinal bleeding (GIB) from different locations or mucosal lesions. We aimed to test this hypothesis. METHODS: Two blinded gastroenterologists independently analyzed source documents from the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial of dabigatran 150 mg BID (D150), dabigatran 110 mg BID (D110) versus warfarin in non-valvular atrial fibrillation (NVAF)...
March 27, 2018: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/29578954/health-care-costs-and-utilization-of-dabigatran-compared-with-warfarin-for-secondary-stroke-prevention-in-patients-with-nonvalvular-atrial-fibrillation-a-retrospective-population-study
#13
Nai-Fang Chi, Ye Wang, Li-Nien Chien, Shu-Chen Chien, Yu Ko
BACKGROUND: It remains unclear whether the use of new oral anticoagulants, compared with warfarin, is economically beneficial in Asian countries. OBJECTIVE: The objective of this study is to compare the health care costs and utilization between dabigatran and warfarin in a real-world nonvalvular atrial fibrillation (NVAF) population. RESEARCH DESIGN: Data were obtained from the Taiwan National Health Insurance Database, and patients with an NVAF diagnosis between June 1, 2012, and May 31, 2014, were identified using the International Classification of Diseases, Ninth Revision code of 427...
March 23, 2018: Medical Care
https://www.readbyqxmd.com/read/29569402/use-of-neutrophil-lymphocyte-ratio-for-risk-stratification-and-relationship-with-time-in-therapeutic-range-in-patients-with-nonvalvular-atrial-fibrillation-a-pilot-study
#14
Kahraman Cosansu, Mehmet Bulent Vatan, Huseyin Gunduz, Ramazan Akdemir
BACKGROUND: Atrial fibrillation is one of the most common abnormal heart rhythms. Neutrophil-lymphocyte ratio (NLR) has emerged as a potential marker for the level of inflammation in cardiac disorders. HYPOTHESIS: NLR might be associated with thrombosis and bleeding risk scores and might predict cardioembolic risk in nonvalvular atrial fibrillation (NVAF) patients within the therapeutic international normalized ratio (INR). METHODS: We enrolled 272 patients taking warfarin for NVAF and classified them into 2 groups: Group A consisted of patients (n = 132) whose time in therapeutic range (TTR) was ≥65%, and Group B comprised patients (n = 139) whose TTR was <65%...
March 22, 2018: Clinical Cardiology
https://www.readbyqxmd.com/read/29566997/-quality-of-care-and-safety-indicators-in-anticoagulated-patients-with-non-valvular-auricular-fibrillation-and-deep-venous-thromboembolic-disease
#15
E Ignacio, J J Mira, F J Campos, E López de Sá, A Lorenzo, F Caballero
OBJECTIVES: To identify and prioritise indicators to assess the quality of care and safety of patients with non-valvular auricular fibrillation (NVAF) and deep vein thrombosis (DVT) treated with anticoagulants. MATERIALS AND METHODS: Using the consensus conference technique, a group of professionals and clinical experts, the determining factors of the NVAF and DVT care process were identified, in order to define the quality and safety criteria. A proposal was made for indicators of quality and safety that were prioritised, taking into account a series of pre-established attributes...
March 19, 2018: Revista de Calidad Asistencial: Organo de la Sociedad Española de Calidad Asistencial
https://www.readbyqxmd.com/read/29564543/impact-of-chronic-kidney-disease-on-watchman-implantation-experience-with-300-consecutive-left-atrial-appendage-closures-at-a-single-center
#16
Xin Xue, Lisheng Jiang, Erich Duenninger, Manuela Muenzel, Shaofeng Guan, Adam Fazakas, Fanzhou Cheng, Juergen Illnitzky, Thorsten Keil, Jiangtao Yu
The prevalence of chronic kidney disease (CKD) is high in patients with atrial fibrillation (AF). Left atrial appendage closure (LAAC) has been recognized as an efficient alternative to oral anticoagulation for the prevention of thromboembolic events in patients with non-valvular AF (NVAF); however, the long-term safety and efficacy of LAAC in patients with CKD remain unclear. This study was designed to provide data regarding the safety and efficacy of LAAC in NVAF patients with CKD. A real-world analysis of the safety and efficacy of LAAC was performed on a cohort of 300 NVAF patients with or without CKD who underwent LAAC using the Watchman (WM) device at our center...
March 22, 2018: Heart and Vessels
https://www.readbyqxmd.com/read/29559181/the-effectiveness-and-safety-of-low-dose-rivaroxaban-in-asians-with-non-valvular-atrial-fibrillation
#17
Hsin-Fu Lee, Yi-Hsin Chan, Hui-Tzu Tu, Chi-Tai Kuo, Yung-Hsin Yeh, Shang-Hung Chang, Lung-Sheng Wu, Lai-Chu See
BACKGROUND: Rivaroxaban (20 mg/15 mg once daily) is an effective and safe alternative to warfarin for stroke prevention in patients with non-valvular AF (NVAF). Low-dose rivaroxaban (15 mg/10 mg once daily) has been only approved for NVAF patients in Japan and Taiwan, although its effectiveness and safety at low doses remain unclear among Asians with NVAF. The objective of the study is to compare the effectiveness and safety of low-dose rivaroxaban to those of warfarin among Asians with NVAF...
March 14, 2018: International Journal of Cardiology
https://www.readbyqxmd.com/read/29544920/phosphatidylserine-exposing-blood-cells-and-microparticles-induce-procoagulant-activity-in-non-valvular-atrial-fibrillation
#18
Lixiu Wang, Yayan Bi, Muxin Yu, Tao Li, Dongxia Tong, Xiaoyan Yang, Cong Zhang, Li Guo, Chunxu Wang, Yan Kou, Zengxiang Dong, Valerie A Novakovic, Ye Tian, Junjie Kou, Masood A Shammas, Jialan Shi
BACKGROUND: The definitive role of phosphatidylserine (PS) in the prothrombotic state of non-valvular atrial fibrillation (NVAF) remains unclear. Our objectives were to study the PS exposure on blood cells and microparticles (MPs) in NVAF, and evaluate their procoagulant activity (PCA). METHODS: NVAF patients without (n = 60) and with left atrial thrombi (n = 18) and controls (n = 36) were included in our study. Exposed PS was analyzed with flow cytometry and confocal microscopy...
May 1, 2018: International Journal of Cardiology
https://www.readbyqxmd.com/read/29519351/non-vitamin-k-antagonist-oral-anticoagulants-and-risk-of-serious-liver-injury
#19
Antonios Douros, Laurent Azoulay, Hui Yin, Samy Suissa, Christel Renoux
BACKGROUND: Non-vitamin K antagonist oral anticoagulants (NOACs) are relatively new drugs used for stroke prevention in nonvalvular atrial fibrillation (NVAF). However, there are concerns that their use may be associated with hepatotoxic effects. OBJECTIVES: The purpose of this study was to determine whether the use of NOACs is associated with an increased risk of serious liver injury compared with the use of vitamin K antagonists (VKAs) in NVAF patients with and without prior liver disease...
March 13, 2018: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/29517050/anticoagulation-for-atrial-fibrillation-after-intracranial-hemorrhage-a-systematic-review
#20
REVIEW
Maximiliano A Hawkes, Alejandro A Rabinstein
Background: We summarize the existing evidence on the potential benefit of oral anticoagulation (OAC) in intracerebral hemorrhage (ICH) survivors with nonvalvular atrial fibrillation (NVAF). Methods: Systematic review of the literature to address the following issues: (1) prevalence of NVAF in ICH survivors, (2) current prescription of OAC, (3) factors associated with resumption of OAC, (4) risk of ischemic stroke (IS) and recurrent ICH, and (5) ideal timing for restarting OAC in ICH survivors with NVAF...
February 2018: Neurology. Clinical Practice
keyword
keyword
83853
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"